semaglutide 2.4 mg obesity 2·4 once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial semaglutide 2.4 mg weekly Efficacy

FDA Approval Timeline (as of May 2026) The TRIUMPH-1 readout reported on May 21, 2026 was the first pivotal Phase 3 weight-loss readout for retatrutide [1][2]

Many report feeling more energetic within the first week

Lee Y, Kang H, Lee B, Zhang Y, Kim Y, Kim S, et al

One 52yo reversed prediabetes markers

A study performed by Wang Z [35] found that when comparing diets where the main protein source was red meat, white meat and non-meat protein sources, consumption of red meat increased the production of TMAO, whereas white meat and non-meat protein diets generated only low to negligible amounts TMAO

CAUTION: Do not exceed suggested use